This HTML5 document contains 159 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://dx.doi.org/10.1111/
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q33854032
rdf:type
wikibase:Item
schema:description
2009年论文 artículu científicu espublizáu en 2009 article scientifique (publié 2009) article científic 2009年论文 научни чланак artikull shkencor article scientific мақолаи илмӣ 2009年論文 tudományos cikk სამეცნიერო სტატია artigo científico (publicado na 2009) מאמר מדעי 2009年の論文 مقالة علمية 2009年论文 artigo científico (publicado na 2009) artículo científico publicado en 2009 bilimsel makale articolo scientifico مقالهٔ علمی 2009年论文 vedecký článok 2009年論文 научна статия 2009年論文 artikulong pang-agham سائنسی مضمون 2009年論文 2009 թուականի Մարտին հրատարակուած գիտական յօդուած 2009 թվականի մարտին հրատարակված գիտական հոդված 2009년 논문 tieteellinen artikkeli vetenskaplig artikel vědecký článek научни чланак наукова стаття, опублікована в березні 2009 vitenskapelig artikkel мақолаи илмӣ επιστημονικό άρθρο 2009年論文 wetenschappelijk artikel ২০০৯-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ teaduslik artikkel naučni članak 2009年论文 videnskabelig artikel (udgivet 2009) บทความทางวิทยาศาสตร์ научная статья 2009年论文 scienca artikolo scientific article bài báo khoa học mokslinis straipsnis artigo científico articol științific vitskapeleg artikkel 2009 nî lūn-bûn artykuł naukowy wissenschaftlicher Artikel
p:P577
wds:Q33854032-A07D8E01-06AC-4295-A4F3-395FA07C926C
wdt:P577
2009-03-01T00:00:00Z
p:P407
wds:Q33854032-40462B6C-5471-4BA2-BA92-2BCA82668C5B
wdt:P407
wd:Q1860
p:P2860
wds:Q33854032-E27ECF7F-C6CD-4482-90DE-8042467EFEBF wds:Q33854032-E53C3F23-1FDB-4410-9F72-119CD177953F wds:Q33854032-D4ACF735-4C25-4453-BE66-3E0C4A8EDD99 wds:Q33854032-D6B9331C-A65F-4CC2-9C2B-385F3A9ED9BD wds:Q33854032-FCEED718-3136-4550-9E06-5F58485037A2 wds:Q33854032-63F0E0D7-BB7D-4694-B62F-330B56199F75 wds:Q33854032-680A21F6-A700-41A9-8EFF-6CC3878D32F7 wds:Q33854032-6C727AB1-58A4-4C1A-8A90-71F6A498163C wds:Q33854032-70C4B6AD-7C67-4E49-8EED-3BDF81364E49 wds:Q33854032-C19DA1FB-8685-4DBC-B8A4-F8A9DF46400B wds:Q33854032-85FBB140-3663-43D3-B555-AF0168463C10 wds:Q33854032-94A84C8D-A012-4C56-81E2-28B77D1F4D73 wds:Q33854032-2351686F-030E-44EF-9C29-286CA423FA61 wds:Q33854032-0F15BF3F-D7EF-44F5-8A5C-A4C2AE4A2D8A wds:Q33854032-13CC1917-D6C1-4E88-AE85-702A079D7EDE wds:Q33854032-48A40DB6-0617-483E-8C42-387FD5F2CDA9 wds:Q33854032-26B7093C-A9CE-43D6-8FA2-7000BC833D32
wdt:P2860
wd:Q28273497 wd:Q46828447 wd:Q34598940 wd:Q44865459 wd:Q36549321 wd:Q47296454 wd:Q80572896 wd:Q28378259 wd:Q28373115 wd:Q46804042 wd:Q46344895 wd:Q40585257 wd:Q36861069 wd:Q51468797 wd:Q45124469 wd:Q44244716 wd:Q51015452
p:P2093
wds:Q33854032-15E348DC-E789-4981-9436-6BF1B745E2DD wds:Q33854032-2AB58C13-868C-4C46-97DB-3532B445C133 wds:Q33854032-503E275F-3F2B-4686-A2B6-599B118629B8 wds:Q33854032-563FB539-0F47-4BBB-A0C5-8C741DE3A3E6 wds:Q33854032-77C4F6B8-7549-4647-B735-7416BE10A592 wds:Q33854032-C02B041C-DC95-4EA2-901B-816DE70A60D8 wds:Q33854032-EA877CD3-D9D4-42B5-BC35-52119B96CD44 wds:Q33854032-F0EE6CB6-6CC6-42BB-AEB5-7CFF427795A5
wdt:P2093
J Strand M Brändle T D Le Thi M Zdravkovic LEAD-1 SU study group J Shaw N A Kamaruddin W M W Bebakar
rdfs:label
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
skos:prefLabel
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
schema:name
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
p:P50
wds:Q33854032-48DEB63B-B2DA-4EDB-A794-21B465BC15D3 wds:Q33854032-2589D1FA-A28D-4501-8D22-10B2471DE9B1
wdt:P50
wd:Q37631006 wd:Q39619836
p:P1476
wds:Q33854032-D5797586-4A2D-4ACA-B87E-2250B7CFAF85
wdt:P1476
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
p:P304
wds:Q33854032-5055E39A-4983-47C6-97D6-4F7E2CC80392
wdt:P304
268-278
p:P31
wds:Q33854032-19FD8FC9-2127-442F-AB9F-9B2C8E493470
wdt:P31
wd:Q13442814
p:P921
wds:Q33854032-23655CAA-983F-4872-8798-756DE73AD657 wds:Q33854032-F402A130-D689-4778-BA0D-A4CF86501FF5 wds:Q33854032-7A5CA4FD-FAF1-4AF4-B232-05016E844887 wds:Q33854032-3030001E-D0A4-493F-BF58-ADE4E742469D
wdt:P921
wd:Q2526479 wd:Q3025883 wd:Q424771 wd:Q269829
p:P698
wds:Q33854032-51E24F4D-43DC-49CD-8A03-02678E53951C
wdtn:P698
n12:19317822
wdt:P698
19317822
p:P1433
wds:Q33854032-0F49ECD1-82A9-4CFB-8C82-9BB7CDC1D3A1
wdt:P1433
wd:Q15758639
p:P433
wds:Q33854032-ECA84921-E8C5-43F0-B51E-BB6759453E12
p:P478
wds:Q33854032-C6D977D4-9B0E-4FD2-B588-A3757B6A2E1B
wdt:P433
3
wdt:P478
26
p:P356
wds:Q33854032-313A587A-91BF-4400-A608-883892A9B5F0
wdtn:P356
n9:J.1464-5491.2009.02666.X
wdt:P356
10.1111/J.1464-5491.2009.02666.X
p:P5875
wds:Q33854032-B16B636C-61C9-4DB2-A505-EA751FD4EAC4
wdt:P5875
24230880
p:P932
wds:Q33854032-6220E82C-CF9C-4F24-B448-D94DF2DBAA72
wdt:P932
2871176